Tourmaline Bio To Present At The Guggenheim Securities SMID Cap Biotech Conference
Date
1/27/2025 7:16:53 AM
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:
Guggenheim Securities SMID Cap Biotech Conference, New York
Fireside Chat
Wednesday, February 5, 2025, at 1:30 pm ET
A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com .
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on LinkedIn or X .
Media Contact
Scient PR
Sarah Mishek
...
Investor Contact
Meru Advisors
Lee M. Stern
...
MENAFN27012025004107003653ID1109132849
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.